T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Flowers Foods
FLO
$1.6B
| $2.19M | ﹤0.01% |
200,893
+5,810
| +3% | +$67.5K |
|
1702
The GEO Group
GEO
$4.02B
| $2.19M | ﹤0.01% |
135,603
+4,442
| +3% | +$74.1K |
|
1703
First Busey Corp
BUSE
$2.57B
| $2.18M | ﹤0.01% |
91,788
+3,727
| +4% | +$87.6K |
|
1704
Diodes
DIOD
$4.71B
| $2.17M | ﹤0.01% |
44,023
+2,558
| +6% | +$129K |
|
1705
Innospec
IOSP
$2.31B
| $2.17M | ﹤0.01% |
28,383
+5,021
| +21% | +$379K |
|
1706
National Bank Holdings
NBHC
$1.94B
| $2.16M | ﹤0.01% |
56,866
+5,270
| +10% | +$199K |
|
1707
DXC Technology
DXC
$1.74B
| $2.16M | ﹤0.01% |
147,143
-8,700
| -6% | -$120K |
|
1708
Central Garden & Pet Co
CENT
$2.75B
| $2.15M | ﹤0.01% |
66,978
+3,086
| +5% | +$98.5K |
|
|
EFOR
1709
Everforth Inc
EFOR
$1.3B
| $2.15M | ﹤0.01% |
44,603
-41,492
| -48% | -$1.91M |
|
1710
Acushnet Holdings
GOLF
$5.24B
| $2.14M | ﹤0.01% |
26,851
-724
| -3% | -$58.8K |
|
1711
Cheesecake Factory
CAKE
$5.6B
| $2.14M | ﹤0.01% |
42,348
+1,385
| +3% | +$69.5K |
|
1712
BancFirst
BANF
$3.88B
| $2.12M | ﹤0.01% |
20,031
+668
| +3% | +$75.6K |
|
1713
Matthews International
MATW
$725M
| $2.12M | ﹤0.01% |
81,127
+606
| +0.8% | +$14.9K |
|
1714
Clearway Energy Class C
CWEN
$7.03B
| $2.12M | ﹤0.01% |
63,722
+2,917
| +5% | +$97.1K |
|
1715
Banner Corp
BANR
$2.5B
| $2.12M | ﹤0.01% |
33,787
+1,896
| +6% | +$120K |
|
1716
Helios Technologies
HLIO
$2.67B
| $2.11M | ﹤0.01% |
39,490
+1,440
| +4% | +$77.6K |
|
|
HI
1717
DELISTED
Hillenbrand
HI
| $2.1M | ﹤0.01% |
66,289
+2,796
| +4% | +$86.1K |
|
1718
Ashland
ASH
$3.35B
| $2.1M | ﹤0.01% |
35,816
+1,485
| +4% | +$78.5K |
|
1719
Dentsply Sirona
XRAY
$2.33B
| $2.1M | ﹤0.01% |
183,673
-13,699
| -7% | -$161K |
|
1720
Avis
CAR
$4.87B
| $2.1M | ﹤0.01% |
16,324
+623
| +4% | +$86.9K |
|
1721
Golar LNG
GLNG
$5.32B
| $2.09M | ﹤0.01% |
56,193
+1,436
| +3% | +$54.9K |
|
|
MPT
1722
Medical Properties Trust
MPT
$2.47B
| $2.08M | ﹤0.01% |
416,905
-4,059
| -1% | -$21.1K |
|
1723
Plug Power
PLUG
$3.2B
| $2.08M | ﹤0.01% |
1,058,016
+233,101
| +28% | +$609K |
|
1724
Ocular Therapeutix
OCUL
$2.17B
| $2.08M | ﹤0.01% |
171,524
+39,960
| +30% | +$485K |
|
1725
Atkore
ATKR
$3.17B
| $2.07M | ﹤0.01% |
32,783
-2,637
| -7% | -$172K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.